Can-fite Biopharma Ltd. cash flow statement

In fiscal 2025, Can-fite Biopharma Ltd.'s operations generated −$8.9m of cash; it spent $2,000 on capital projects, leaving free cash flow of −$9.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Can-fite Biopharma Ltd.: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−4	−11	−12	−10	−11	−8	−8	−9
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	—	—	0	0	0	0	0	0
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−4	−11	−12	−10	−11	−8	−8	−9
Free cash flow after stock pay	—	—	−12	−10	−11	−9	−8	−9
Dividends paid	—	—	1	3	—	—	—	—
Shares issued	—	—	—	—	—	—	2	3

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CANF vs CRVO CANF vs CRDF CANF vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Can-fite Biopharma Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Can-fite Biopharma Ltd.